Navigation Links
Antibodies linked to cardiovascular disease increase in patients with active lupus
Date:2/24/2010

A study by researchers in Australia and the United Kingdom suggests that autoantibodies to fat binding proteins significantly increase in systemic lupus erythematosus (SLE) patients with active disease. This increase in anti-apolipoprotein (anti-Apo A-I), anti-high-density lipoprotein (anti-HDL), and anti-C-reactive protein (anti-CRP) may contribute to the development of atherosclerosis in SLE patients, placing them at risk for cardiovascular disease (CVD). Complete findings of this study are available in the March issue of Arthritis & Rheumatism, published by Wiley-Blackwell on behalf of the American College of Rheumatology.

Lupus is a chronic autoimmune disease where the immune system creates antibodies that attack an individuals' own cells, causing inflammation throughout the body. The inflammation leads to tissue and organ damage, affecting the heart, kidneys, lungs, brain, blood, skin and/or joints of those with SLE. According to a 2008 study for the National Arthritis Data Workgroup 322,000 Americans have a definite or probable SLE diagnosis. The Lupus Foundation of America's figures are much higher, with up to 1.5 million in the U.S. and close to 5 million worldwide reported having form (SLE, discoid, sub-acute cutaneous, drug-induced, or neonatal) of lupus.

In the current study serum levels of anti-Apo A-I, anti-HDL, and anti-CRP were taken from participants that included 39 SLE patients with high disease activity over the previous 2-year period; 42 SLE patients with low disease activity over the previous 2 years; 16 patients newly diagnosed with lupus nephritis (inflammation of the kidney caused by SLE); 25 patients with samples obtained at the time of a SLE flare and during inactivity of the disease; 24 SLE patients who had prior CVD events; and 34 healthy subjects in the control.

Researchers found that antibodies above the upper limit of normal (ULN) were higher in patients in the high disease activity group compared with the low disease activity group: anti-Apo A-I were higher in 35.9% vs. 12% of subjects; anti-HDL levels at 44.7% vs. 30.9%; and anti-CRP at 26.3% vs. 12.8%. Results further indicate that in 55% of the subjects, anti-Apo A-I levels were higher at the time of a disease flare compared with only 34.5% in preflare samples. "The main finding in our study was that levels of anti-Apo A-I and anti-HDL were significantly higher in patients with greater disease activity than in those with less active disease over the same period," said the authors.

In her editorial also published in Arthritis & Rheumatism, Bevra Hahn, M.D., from the David Geffen School of Medicine at the University of California Los Angeles, acknowledged that the study by O'Neill et al provided a novel method for studying association of autoantibodies with active disease by classifying SLE patients according to sustained chronic disease activity (or not) instead of the traditional approach of using a validated scoring system that identifies active disease at one point in time. "While this is an important step, measuring antibodies to Apo A-I, HDL or CRP in SLE patients has not yet reached the point where it can be used routinely to identify risk of accelerated atherosclerois," commented Dr. Hahn. "As risk prediction models emerge over the next few years, these antibodies may be included along with other predisposing variables."


'/>"/>

Contact: Dawn Peters
medicalnews@wiley.com
781-388-8408
Wiley-Blackwell
Source:Eurekalert

Related medicine news :

1. Low levels of natural antibodies behind stroke
2. Dana-Farber and Sanford-Burnham Institute license flu-targeting antibodies to Genentech and Roche
3. Biological catch-22 prevents induction of antibodies that block HIV
4. Reportlinker Adds The Future of Monoclonal Antibodies - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
5. New findings suggest strategy to help generate HIV-neutralizing antibodies
6. FDA Approves Donor Screening Test for Antibodies to HIV
7. ForteBio Launches Dip and Read(TM) Immunogenicity Assay Kit for Rapid Detection of Anti-Drug Antibodies
8. NIAID Awards New Grant to Expand Studies of Peregrines Anti-PS Antibodies to Treat Viral Hemorrhagic Fevers
9. MMR Information Systems, Inc. Receives Licensing Proposal Involving the Companys Anti-CD20 Antibodies
10. Autoantibodies may be created in response to bacterial DNA
11. ForteBio Launches New Biosensor for Kinetic Analysis and Screening of Human IgG Antibodies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/29/2016)... Newport Beach, Calif. (PRWEB) , ... April 29, 2016 , ... ... affect us. An effective way to confront and deal with these stressors is to ... taste bad to be good for you. Risa Groux, a certified Holistic Nutritionist and ...
(Date:4/29/2016)... ... April 29, 2016 , ... ... more flexibility in repaying their loans, more information about their loan terms and ... total outstanding student loan debt, including federal and private loans, has reached $1.3 ...
(Date:4/29/2016)... (PRWEB) , ... April 29, 2016 , ... Spine Team ... pain, is proud to announce one of their physicians has been invited to be ... Physicians (Texas ACOFP) Family Practice Review conference on April 30, 2016. , Dr. ...
(Date:4/29/2016)... ON (PRWEB) , ... April 29, 2016 , ... ... and the Canadian Celiac Association (CCA), is pleased to announce the launch of ... gluten-free products, nutritional articles, recipes, and more. The purpose of the GFCP ...
(Date:4/29/2016)... ... , ... Reltok Nasal Products proudly announces that Boston Medical Products, Inc., a ... throat specialty, has added the KOTLER NASAL AIRWAY™ to its diverse product line. , ... patented safety device secured by nasal surgeons onto the floor of the nasal passages, ...
Breaking Medicine News(10 mins):
(Date:4/29/2016)... -- Glycotope GmbH, a clinical-stage immuno-oncology company ... of Dr. Alfredo Zurlo as Chief Medical ... many years clinical experience and a proven track record ... was at Mologen AG where he was Chief Medical ... Zurlo held various positions at F Hoffmann La Roche ...
(Date:4/28/2016)... , April 28, 2016 ... "Global Plastic Surgery Products Market 2016-2020" report ... ) , The global plastic surgery ... of 9.47% during the period 2016-2020. , ,The growing ... leading to the growth of the market. Lasers are ...
(Date:4/28/2016)... 28, 2016 Treato , ... healthcare, announced today that it has been named a ... Vendor in Life Sciences, 2016, Stephen Davies ... report focuses on life-science- oriented analytics, algorithms and smart ... and doctors, confirm medication ingestion, and analyze unstructured information. ...
Breaking Medicine Technology: